Latest Pathology News

Charter Hall Social Infrastructure REIT (ASX:CQE) posted a robust FY26 result with a 13.1% rise in operating earnings per unit, driven by strategic acquisitions and disciplined capital recycling. The portfolio now boasts a $2.3 billion valuation, near-full occupancy, and extended lease terms, underpinning income resilience amid ongoing sector demand.

Charter Hall Long WALE REIT (ASX:CLW) reported steady operating earnings growth and reinforced its long WALE portfolio quality for FY26, alongside a $2 billion debt refinancing and enhanced sustainability credentials.

Healius Limited posted a modest revenue increase and underlying loss improvement for FY26, overshadowed by a substantial non-cash goodwill impairment and ongoing sector pressures.

Pro Medicus delivered a robust FY26 with 28% underlying revenue growth, a surge in new contract wins worth $407 million, and a 25% increase in fully franked dividends, underpinned by strong AI product development and rapid implementations.

Australian Clinical Labs (ASX: ACL) delivered a modest 1.7% underlying EBIT increase in FY26, navigating subdued revenue and rising labour costs with operational efficiencies and strategic initiatives.

Mayfield Childcare's Mayfield 360 division has achieved registration as an NDIS provider, enabling it to expand early intervention support services and transition from pilot to billable operations.

Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.

Charter Hall Long WALE REIT reported a 128% surge in statutory profit to $275.9 million for FY26, supported by a $150.7 million property revaluation gain and a $248 million net acquisition spree. The REIT also completed a $2 billion debt refinancing, extending maturities and cutting margins.

NeuroScientific Biopharmaceuticals (ASX:NSB) has locked in a key FDA Pre-IND meeting for late August, advancing its Phase 2 trial plans for StemSmart™ targeting refractory Crohn’s disease in the US and Australia.

Charter Hall Social Infrastructure REIT (ASX:CQE) reported a 13.1% rise in operating earnings per unit for FY26, driven by strategic acquisitions and strong rental growth, while raising guidance for FY27.

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.